A CNS-Active siRNA Chemical Scaffold for the Treatment of Neurodegenerative Diseases
Authors
Alterman, Julia F.Faculty Advisor
Anastasia KhvorovaAcademic Program
Interdisciplinary Graduate ProgramUMass Chan Affiliations
RNA Therapeutics InstituteDocument Type
Doctoral DissertationPublication Date
2019-05-13Keywords
RNAisiRNA
Huntington's disease
neurodegenerative disease
brain
delivery
Biotechnology
Chemical and Pharmacologic Phenomena
Medical Biotechnology
Medical Neurobiology
Medicinal Chemistry and Pharmaceutics
Neurosciences
Nucleic Acids, Nucleotides, and Nucleosides
Other Neuroscience and Neurobiology
Pharmaceutics and Drug Design
Translational Medical Research
Metadata
Show full item recordAbstract
Small interfering RNAs (siRNAs) are a promising class of drugs for treating genetically-defined diseases. Therapeutic siRNAs enable specific modulation of gene expression, but require chemical architecture that facilitates efficient in vivodelivery. siRNAs are informational drugs, therefore specificity for a target gene is defined by nucleotide sequence. Thus, developing a chemical scaffold that efficiently delivers siRNA to a particular tissue provides an opportunity to target any disease-associated gene in that tissue. The goal of this project was to develop a chemical scaffold that supports efficient siRNA delivery to the brain for the treatment of neurodegenerative diseases, specifically Huntington’s disease (HD). HD is an autosomal dominant neurodegenerative disorder that affects 3 out of every 100,000 people worldwide. This disorder is caused by an expansion of CAG repeats in the huntingtin gene that results in significant atrophy in the striatum and cortex of the brain. Silencing of the huntingtin gene is considered a viable treatment option for HD. This project: 1) identified a hyper-functional sequence for siRNA targeting the huntingtin gene, 2) developed a fully chemically modified architecture for the siRNA sequence, and 3) identified a new structure for siRNA central nervous system (CNS) delivery—Divalent-siRNA (Di-siRNA). Di-siRNAs, which are composed of two fully chemically-stabilized, phosphorothioate-containing siRNAs connected by a linker, support potent and sustained gene modulation in the CNS of mice and non-human primates. In mice, Di-siRNAs induced potent silencing of huntingtin mRNA and protein throughout the brain one month after a single intracerebroventricular injection. Silencing persisted for at least six months, with the degree of gene silencing correlating to guide strand tissue accumulation levels. In Cynomolgus macaques, a bolus injection exhibited significant distribution and robust silencing throughout the brain and spinal cord without detectable toxicity. This new siRNA scaffold opens the CNS for RNAi-based gene modulation, creating a path towards developing treatments for genetically-defined neurological disorders.DOI
10.13028/qx36-6t93Permanent Link to this Item
http://hdl.handle.net/20.500.14038/31246Notes
This thesis received the 2019 Chancellor's Award.
Rights
Licensed under a Creative Commons licenseDistribution License
http://creativecommons.org/licenses/by/4.0/ae974a485f413a2113503eed53cd6c53
10.13028/qx36-6t93
Scopus Count
Except where otherwise noted, this item's license is described as Licensed under a Creative Commons license